ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2025
Potential impact of controlling risk factors on future liver cancer deaths in China.
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mitochondrial function meets oncology: the multifaceted role of TFAM across cancer types.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to quantify the potential impact of controlling major risk factors on liver cancer deaths in China from 2021 to 2050 under various intervention scenarios. Methods: We developed a macro-level simulation model based on comparative risk assessment to estimate population attributable fractions and avoidable liver cancer deaths. Risk factor prevalence data were obtained from national surveys and epidemiological estimates. Three intervention scenarios for each risk factor were projected: elimination (Scenario 1), ambitious reduction (Scenario 2), and manageable targets aligned with national/global goals (Scenario 3). The impact of secondary prevention through liver cancer screening at different coverage was evaluated. Results: Between 2021 and 2050, liver cancer deaths in China are projected to reach 9.44 million in males and 4.29 million in females. Eliminating hepatitis B virus and hepatitis C virus could prevent 65.62% (57.47%-73.77%) and 28.47% (24.93%-32.00%) of liver cancer deaths, respectively. Achieving manageable targets in reducing the prevalence of smoking and alcohol drinking could prevent 6.57% (5.75%-7.38%) and 0.85% (0.75%-0.96%) of liver cancer deaths, with a more pronounced effect observed in males. Eliminating high body mass index (BMI) could avert 45,000 male and 25,000 female deaths annually by 2050, while diabetes elimination could prevent 60,000 male and 21,000 female deaths. Secondary prevention through liver cancer screening with 80% coverage could reduce liver cancer deaths by 3.59% (3.14%-4.04%) for the total population. Combining all interventions under Scenario 1 could prevent up to 88.39% (76.65%-99.81%) of male and 77.80% (67.42%-87.88%) of female liver cancer deaths by 2050. Conclusions: Comprehensive risk factor control could prevent over 80% of liver cancer deaths in China by 2050. Secondary prevention through screening may offer modest additional benefits. These findings provide strong quantitative support for targeted, evidence-based interventions and underscore the need for policy action to address key risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.